Research
Alexander Levitzki is known for developing specific chemical inhibitors of cancer-induced protein kinases. He was the first to develop systematically tyrosine phosphorylation inhibitors (tyrphostins) against a wide spectrum of protein tyrosine kinases. Levitzki demonstrated (1993) that such an inhibitor of Bcr-Abl kinase induces death of chronic myeloid leukemia (CML) cells.This work led to the development of Gleevec by Novartis(1996) that is currently used, with great success, for therapy of patients afflicted by this disease. Levitzki also pioneered the inhibitors of EGF receptor, PDGF receptor, Her-2/neu, Jak-2, VEGFR and peptide based cell permeable PKB/Akt inhibitors. Levitzki also showed that PDGFR kinase inhibitors (PDGFR directed tyrphostins), released from nanoparticles or from a drug eluting stent can be used to inhibit restenosis after balloon angioplasty.
In 2006 his research team developed a method for inducing brain tumor cells to "commit suicide".
Read more about this topic: Alexander Levitzki
Famous quotes containing the word research:
“It is a good morning exercise for a research scientist to discard a pet hypothesis every day before breakfast. It keeps him young.”
—Konrad Lorenz (1903–1989)
“... research is never completed ... Around the corner lurks another possibility of interview, another book to read, a courthouse to explore, a document to verify.”
—Catherine Drinker Bowen (1897–1973)
“After all, the ultimate goal of all research is not objectivity, but truth.”
—Helene Deutsch (1884–1982)